The Future of Diabetes Pharmacological Treatments

In the last decade there has been a rapid growth in the number of substances that have appeared in the fight against diabetes. Following this trend, it is also certain that more potential substances to fight diabetes will be discovered in the future. The main goal in diabetes control drugs is achieving the reduction of blood sugar while at the same time helping individuals lose weight. Today there are two types of diabetes medications used for this effect: disaccharides inhibitors and medications based on metmorfin. It is important to remember that the system involved in the metabolism of sugars is extremely complex and still not fully understood. As more is known about the mechanisms involved, more possible chemicals will be discovered for insulin sensitivity, insulin receptors, blood sugar metabolism, and the way the body handles and manages the levels of sugar in the blood.

A promising agent for the future is Amylin, a protein composed of 37 amino acids that is produced at the same time as insulin. This substance has an effect on digestion and on the secretion of glucagon. A key to understanding Amylin in type one diabetes, where this substance is affected just as much as insulin. We should remember that type one diabetes, previously known as juvenile diabetes, is due to a deficient or absent insulin-producing mechanism. Some synthetic substitutes for Amylin are now in development and early tests show promising results.

Another area of interest in diabetes pharmacological research are Beta-3 antagonists. These agents have been linked with the body’s natural reaction to an increase in sugar absorption. Treatment with these compounds may allow lowering blood sugar levels while at the same time reducing the levels of abdominal fat cells.

In the last decade, substances that were once quite difficult to acquire have become freely available for the treatment of diabetes. Advances in controlling and monitoring blood sugars have also led to a decrease in diabetes mortality and cases of type two diabetes. However, there are still advances to be made in understanding the cardiovascular effects that comprise the vast majority of diabetes deaths around the world. Damage to the coronary arteries, as well as those that deliver blood to the brain and to the other important organs are the most important cause of death in diabetic patients, rather than microvascular disorders. It is still also quite uncertain whether the improvement in cardiovascular factors is truly due to the reduction of sugar in the blood or whether this is due to the weight loss and reduction in blood pressure that necessarily must accompany treatment for type two diabetes.

There are also possible advances in the future of insulin treatments. The first is the development of better forms of synthetic insulin, which may allow more stability and better control of sugar levels in the blood. This could also lead to a reduction of the necessary dosages for achieving normal blood sugar levels. The second possible change in the future of insulin therapy is insulin that is not injected, but rather inhaled, for patients with type two diabetes.

Next Post → ← Previous Post